Novavax (LTS:0UP6) Ending Cash Position : $496 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novavax Ending Cash Position?

Novavax's Ending Cash Position for the quarter that ended in Mar. 2024 was $496 Mil.

Novavax's quarterly Ending Cash Position declined from Sep. 2023 ($666 Mil) to Dec. 2023 ($584 Mil) and declined from Dec. 2023 ($584 Mil) to Mar. 2024 ($496 Mil).

Novavax's annual Ending Cash Position declined from Dec. 2021 ($1,528 Mil) to Dec. 2022 ($1,349 Mil) and declined from Dec. 2022 ($1,349 Mil) to Dec. 2023 ($584 Mil).

Novavax Ending Cash Position Historical Data

The historical data trend for Novavax's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Ending Cash Position Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

82.18

648.74

1,528.26

1,348.85

583.81

Novavax Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															636.94	517.94	666.36	583.81	495.94

Novavax Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Novavax's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1348.845	+	-765.035
	=	584

Novavax's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	583.81	+	-87.874
	=	496

Novavax Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Novavax's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (LTS:0UP6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (LTS:0UP6) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (LTS:0UP6) Headlines

No Headlines